Heron Therapeutics | HRTX - Vertriebs- Und Verwaltungskosten

Aktienkurs
0.85
Täglich Wechseln
0.03 4.10%
Monatlich
-12.06%
Jährlich
-55.34%
Q2 Prognose
0.83




Vertriebs- Und Verwaltungskosten Veränderung Datum
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 18.97M 1.03M 2025-12
ANI Pharmaceuticals USD 82.79M 6.13M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Esperion Therapeutics USD 39.42M 456K 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Merck USD 2.85B 215M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Omeros USD 11.32M 2.48M 2024-09
Pacira USD 91.87M 70K 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Surmodics USD 11.4M 3.18M 2025-06
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Veracyte USD 43.31M 8.43M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12